Oct 2025
ILDS Young Dermatologist International Achievement Award
One of six young dermatologists honoured at the 4th ILDS World Skin Summit in Cape Town, South Africa, representing the British Association of Dermatologists.
Activity.
A curated feed of recent activity, pulled from public sources including the NIHR Manchester BRC, Northern Care Alliance Research, the British Association of Dermatologists, the Psoriasis Association and the DPRG account on LinkedIn. Each item links to its source.
2025
2025
Named touchDERMATOLOGY Future Leader 2025
Featured in the touchDERMATOLOGY Future Leaders cohort with a short interview on evidence-based dermatology and pharmacoepidemiology.
2024
Aug 2024
MERMAID begins — £1.4 m MRC Clinician Scientist Fellowship
Five-year MRC fellowship to develop methods that combine randomised trial data with registry-based observational data across psoriasis, rheumatology and inflammatory bowel disease.
Sep 2024
BAD blog — how to design a clinical research study (parts 1 & 2)
Two-part BAD blog series on framing a research question and choosing the right study design to answer it — covering estimands, randomised controlled trials and registry-based studies.
2024
Psoriasis Association 2024 Conference talk — what’s new from BADBIR
Invited talk: “Increasing understanding of biologic treatment: what’s new from the BAD Biologics Register (BADBIR)?”
2023
Jun 2023
Update on new psoriasis treatments and research findings
Long-form interview from the Psoriasis Association Conference covering the state of biologic therapies, real-world evidence and what’s next for treatment selection in psoriasis.
2021
2021
Psoriasis Association 2021 Conference talk — biosimilar uptake from BADBIR
“Evaluation of TNF inhibitor biosimilar use in the UK: a study from BADBIR” — describing the early uptake of biosimilars for psoriasis using register data.
Selected media commentary
Ongoing
Expert commentary on biologics and biosimilars in psoriasis
Quoted across HCPLive on adalimumab biosimilar uptake, biosimilar safety and effectiveness, and on guselkumab drug persistence in psoriatic disease.
Adalimumab biosimilars · Biosimilar safety · Guselkumab persistence
From LinkedIn
Now
Follow on LinkedIn
Day-to-day posts, reposts and comments live on LinkedIn. LinkedIn doesn’t expose a stable public API for posts, so the activity below is hand-curated from publicly indexed posts — for the full feed, follow the profile.
Mar 2023
Recruiting a dermatology specialist trainee for a one-year BADBIR research post
Post highlighting a funded research opportunity within the BADBIR programme for dermatology specialty trainees.
Ongoing
NCA Research featured profile
Profiled by the Northern Care Alliance Research account as one of the trust’s clinician researchers.
Curated, not auto-fetched. To suggest an addition email zenas.yiu@manchester.ac.uk.